Moleculin Biotech Inc

Moleculin Biotech Inc operates with a market capitalization of $11.74 million and a price-to-book ratio of 0.66, indicating a significant discount to its book value. The company holds $10.85 million in cash and equivalents, while its total liabilities amount to $7.87 million, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 2.39, which suggests strong short-term liquidity. The company's profitability metrics are negative, with a return on equity of -24.39% and a return on assets of -16.89%, reflecting ongoing losses. The operating cash flow is -$12.67 million, and the free cash flow is -$4.29 million, indicating that the company is not generating positive cash from operations and is likely relying on financing activities to sustain operations. Moleculin Biotech Inc does not report revenue, and its operating income is -$6.19 million, with a net loss of -$4.32 million. The company's capital expenditures are minimal at -$13,000, suggesting limited investment in physical assets. The company's financial structure is characterized by a high proportion of equity, with total equity of $17.71 million and no long-term debt. The company's growth trajectory is not evident from the current financial data, as there is no revenue to analyze for growth. The company is in a development phase, and its future growth will depend on the success of its clinical trials and the commercialization of its products. The company's outlook for the current fiscal year is not provided, but the absence of revenue and the presence of significant losses suggest a challenging path to profitability. The risk assessment for Moleculin Biotech Inc indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and the risk assessment does not identify any significant dilution sources in the near term. The company's financial structure, with no long-term debt and a high current ratio, supports its liquidity position. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's analyst estimates suggest a wide range of price targets, with a mean of $21.00 and a median of $22.00, indicating a positive outlook from analysts despite the company's current financial position. The mean recommendation is 2.00, which is a "Buy" rating, with three "Buy" ratings and no "Strong Buy" or "Hold" ratings.